Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years - PubMed (original) (raw)

. 2016 Oct;48(4):1389-1398.

doi: 10.4143/crt.2015.410. Epub 2016 Apr 11.

Kyung Sun Ha 2, Yun Hwa Jung 3, Hye Sung Won 4, Ho Jung An 5, Guk Jin Lee 6, Donghoon Kang 2, Ji Chan Park 7, Sarah Park 2, Jae Ho Byun 1, Young Jin Suh 8, Jeong Soo Kim 9, Woo Chan Park 10, Sang Seol Jung 11, Il Young Park 12, Su-Mi Chung 13, In Sook Woo 3

Affiliations

Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years

Ji Hyung Hong et al. Cancer Res Treat. 2016 Oct.

Abstract

Purpose: Breast cancer treatment has progressed significantly over the past 20 years. However, knowledge regarding male breast cancer (MBC) is sparse because of its rarity. This study is an investigation of the clinicopathologic features, treatments, and clinical outcomes of MBC.

Materials and methods: Clinical records of 59 MBC patients diagnosed during 1995-2014 from seven institutions in Korea were reviewed retrospectively.

Results: Over a 20-year period, MBC patients accounted for 0.98% among total breast cancer patients, and increased every 5 years. The median age of MBC patientswas 66 years (range, 24 to 87 years). Forty-three patients (73%) complained of a palpable breast mass initially. The median symptom duration was 5 months (range, 1 to 36 months). Mastectomy was performed in 96% of the patients. The most frequent histology was infiltrating ductal carcinoma (75%). Ninety-one percent of tumors (38/43) were estrogen receptor-positive, and 28% (11/40) showed epidermal growth factor receptor 2 (HER-2) overexpression. After curative surgery, 42% of patients (19/45) received adjuvant chemotherapy; 77% (27/35) received hormone therapy. Five out of ten patients with HER-2 overexpressing tumors did not receive adjuvant anti-HER-2 therapy, while two out of four patients with HER-2 overexpressing tumors received palliative trastuzumab for recurrent and metastatic disease. Letrozole was used for one patient in the palliative setting. The median overall survival durations were 7.2 years (range, 0.6 to 17.0 years) in patients with localized disease and 2.9 years (range, 0.6 to 4.3 years) in those with recurrent or metastatic disease.

Conclusion: Anti-HER-2 and hormonal therapy, except tamoxifen, have been underutilized in Korean MBC patients compared to female breast cancer patients. With the development of precision medicine, active treatment with targeted agents should be applied. Further investigation of the unique pathobiology of MBC is clinically warranted.

Keywords: Male breast neoplasms; Prognosis; Survival.

PubMed Disclaimer

Conflict of interest statement

relevant to this article was not reported.

Figures

Fig. 1.

Fig. 1.

Patients diagram. FBC, female breast cancer; MBC, male breast cancer; HER-2, human epidermal growth factor receptor 2; HR, hormone receptor; LN, lymph node.

Fig. 2.

Fig. 2.

(A) Overall survival (OS) of total male patients with breast cancer. (B) OS of male patients with localized breast cancer. (C) Disease-free survival (DFS) of male patients with localized breast cancer.

Similar articles

Cited by

References

    1. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–4. - PubMed
    1. Stang A, Thomssen C. Decline in breast cancer incidence in the United States: what about male breast cancer? Breast Cancer Res Treat. 2008;112:595–6. - PubMed
    1. Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treat. 2009;115:429–30. - PubMed
    1. Ministry of Health and Welfare. Korea Central Cancer Registry. National Cancer Center . Annual report of cancer statistics in Korea in 2012. Goyang: National Cancer Center; 2012.
    1. Baek JM, Sung GY, Lee DS, Kim W, Park IY, Jung SS, et al. Male breast cancer. J Breast Cancer. 2005;8:123–7.

MeSH terms

Substances

LinkOut - more resources